Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Change in Inventory (2018 - 2025)

UroGen Pharma (URGN) has disclosed Change in Inventory for 7 consecutive years, with $8.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Inventory rose 397.43% year-over-year to $8.1 million, compared with a TTM value of $7.2 million through Dec 2025, up 103.63%, and an annual FY2025 reading of $7.2 million, up 103.63% over the prior year.
  • Change in Inventory was $8.1 million for Q4 2025 at UroGen Pharma, up from $1.2 million in the prior quarter.
  • Across five years, Change in Inventory topped out at $8.1 million in Q4 2025 and bottomed at -$1.6 million in Q1 2025.
  • Average Change in Inventory over 5 years is $768450.0, with a median of $293000.0 recorded in 2021.
  • The sharpest move saw Change in Inventory surged 1600.0% in 2023, then crashed 332.16% in 2025.
  • Year by year, Change in Inventory stood at $1.0 million in 2021, then crashed by 127.64% to -$283000.0 in 2022, then soared by 337.1% to $671000.0 in 2023, then skyrocketed by 143.37% to $1.6 million in 2024, then skyrocketed by 397.43% to $8.1 million in 2025.
  • Business Quant data shows Change in Inventory for URGN at $8.1 million in Q4 2025, $1.2 million in Q3 2025, and -$462000.0 in Q2 2025.